Ibrutinib combo for newly diagnosed brain lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of ibrutinib, methotrexate, and rituximab for people with newly diagnosed primary CNS lymphoma who cannot have a stem cell transplant. It aims to see if this drug combination can effectively treat the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have primary CNS lymphoma (lymphoma that started in the brain or spinal cord).
- You must be 18 or older and not eligible for a stem cell transplant (for example, because of age or other health conditions).
- You must be able to swallow pills and have adequate kidney, liver, and blood cell counts.
- You may have had one cycle of methotrexate with or without rituximab, but must enroll within 4 weeks of that dose.
- You must not be on more than 8 mg of dexamethasone daily and be able to stop steroids within 7 days of starting treatment.
- You must not have other active cancers, uncontrolled infections, or certain heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies methotrexate, tafasitamab, lenalidomide, and rituximab for primary B-cell lymphoma that starts in the brain/spinal fluid. It aims to see how well this combination works for people who cannot have certain high-dose stem cell treatment.
This trial tests a combination of orelabrutinib, rituximab, and methotrexate in people with newly diagnosed primary CNS lymphoma (a lymphoma mainly in the brain/spinal fluid). The goal is to see how well the treatment works and how safely it can be given.
This trial tests a combination of three drugs (rituximab, methotrexate, and orelabrutinib) plus a PD-1 inhibitor for newly diagnosed or relapsed central nervous system lymphoma. The goal is to see if this new combination can improve outcomes for patients with this rare type of lymphoma.
This trial tests a new drug, zanubrutinib, combined with standard chemotherapy for people recently diagnosed with primary central nervous system lymphoma (a type of brain cancer). It aims to see if this combination is safe and effective.
This trial tests a combination of targeted and chemotherapy drugs for people newly diagnosed with primary central nervous system lymphoma. It aims to see if the combination works better than standard treatment.
This trial tests a combination of chemotherapy drugs to treat lymphoma that started in your brain. The goal is to see if this treatment helps without having to use whole-brain radiation.
Hear when a new Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.